Quick Facts

• Administered as emergency therapy for known or suspected opioid overdose.
• Intended to address severe respiratory depression associated with opioid overdose.
• Used in settings where opioids may be present.

НАРУНЕЛ (Naloxone Hydrochloride Nasal Spray) is a medication utilized for the emergency treatment of known or suspected opioid overdose. Its primary role is to temporarily counteract the effects of opioids in the body, particularly the respiratory and central nervous system depression that is life-threatening. The medication is specifically indicated for immediate administration in non-medical and medical settings where an opioid overdose may have occurred.

It is important to understand that НАРУНЕЛ functions as an initial measure for reversal and is not a substitute for professional emergency medical care. Following the administration of this product, an individual should immediately seek definitive medical assistance to manage the full clinical presentation of an overdose. The medication is designed to provide a window of time for patients awaiting transport to a healthcare facility for comprehensive care.

Eligibility Map: Who can and cannot use НАРУНЕЛ — Official Regulatory Information

The eligibility profile for НАРУНЕЛ (Naloxone Hydrochloride Nasal Spray) is defined by its life-saving role in reversing opioid overdose. Regulatory documents generally prioritize the reversal of life-threatening respiratory depression over standard precautions or restrictions.

Eligibility Scope

Eligibility-Related Restrictions (Conditional Use)

Use is permitted but requires close monitoring for: Opioid-dependent individuals, where abrupt reversal may precipitate severe withdrawal, and patients with pre-existing cardiovascular disorders, due to the risk of adverse cardiac effects upon reversal. This conditional use is mandated by official regulatory labeling.

НАРУНЕЛ Interactions with other medicines and products

Pharmacodynamic Constraints The official regulatory profile for НАРУНЕЛ ( Naloxone Hydrochloride) is primarily structured around its core pharmacodynamic antagonism of opioids and critical preparation constraints. A key interaction listed in regulatory documents is the antagonism of partial opioid agonists (e.g., Buprenorphine) and mixed agonists-antagonists. For these substances, the reversal of central nervous system and respiratory depression may be incomplete or require specific dose consideration, which is a recognized efficacy constraint of the interaction.

Risk with Concomitant Agents The regulatory label specifies that the abrupt reversal of opioid effects poses a heightened risk of serious adverse cardiovascular events (such as ventricular fibrillation) in patients co-administered potentially cardiotoxic agents. This risk is explicitly noted as occurring more frequently in patients with pre-existing cardiovascular disorders, establishing a population-dependent interaction note.

Formal Restrictions and Preparation Rules Use of НАРУНЕЛ is formally contraindicated based on patient history of known hypersensitivity to naloxone hydrochloride or any of the product’s excipients. Furthermore, the active substance has specific timing and mixing rules regarding pharmaceutical preparation: it must not be combined with solutions containing bisulfite, metabisulfite, long-chain or high molecular weight anions, or those with an alkaline pH. Official documents do not explicitly list interactions involving CYP enzymes, food, alcohol, or common herbal products.

НАРУНЕЛ functions as an inhibitor, primarily targeting the late phase of the inward sodium current (INa) in cardiac myocytes. The interaction is concentration-, voltage-, and frequency-dependent. Inhibition of the late INa reduces the intracellular accumulation of sodium ions (Na^+) within the myocardial cell cytosol. The subsequent decrease in intracellular Na^+ concentration modulates the activity of the sodium-calcium exchanger (NCX), specifically mitigating its reverse-mode operation. This modification of the NCX reduces the net influx of calcium ions (Ca^2+) into the cell. The downstream consequence is a reduction in the elevated diastolic Ca^2+ concentration, which occurs under conditions that promote late INa persistence. Decreased diastolic Ca^2+ concentration modulates contractile element activation and reduces ventricular wall tension, leading to a decrease in the oxygen consumption of the myocardium. At higher concentrations, НАРУНЕЛ also functions as an inhibitor of the rapid delayed rectifier potassium current (IKr).

How to Use НАРУНЕЛ

The following instructions define the administration protocol for НАРУНЕЛ (Naloxone Hydrochloride Nasal Spray), intended for the emergency treatment of known or suspected opioid overdose. This information is not a substitute for professional medical advice.

Administration Scope

Instruction Classifications (High-Level)

Resulting Procedural Structure

Standard step sequence:

• Call for emergency medical assistance.
• Administer the initial, single dose of the nasal spray device into one nostril.
• Monitor the individual; if there is no response or if symptoms return, administer a repeat dose in the alternate nostril.
• Continue repeating the dose every 2 to 3 minutes until emergency services arrive or the individual responds.

This use protocol defines a time-critical, response-driven regimen using the single-use intranasal device to act as an immediate countermeasure, which must be followed by definitive medical care.

Evidence for use in Essential Hypertension (High Blood Pressure)

The core research examining the Amlodipine/Valsartan combination focuses on its use in adults with high blood pressure, or essential hypertension. The primary evidence comes from Randomized Controlled Trials (RCTs), a type of study where participants are randomly assigned to groups. These trials are used in research exploring how blood pressure measurements change over time, monitoring physiological strain or stress.

Researchers explored the outcomes measured when combining these two medicines into one pill compared to using the individual components. Studies reported measurements where the combination pill was associated with differences in blood pressure readings compared to taking either Amlodipine or Valsartan by itself. Furthermore, research describes patterns in the percentage of participants taking the combination who attained predefined blood pressure target goals over the trials' short follow-up periods.

Evidence in High-Risk Patient Subgroups

Research also examined the use of the combination in populations focusing on patients with Type 2 Diabetes Mellitus or other factors placing them at a high cardiovascular risk. These studies explored outcomes related to conditions characterized by strain on the body by monitoring blood pressure changes within these defined subgroups. Findings describe patterns where the blood pressure changes measured in these high-risk patients were observed in a manner similar to the general hypertensive population studied.

Research Gaps and What Remains Uncertain about НАРУНЕЛ

One important limitation is that long-term effects are not fully established specifically for the fixed-dose combination over many years. Comparative evidence is lacking in high-certainty RCTs that would directly assess long-term outcomes of this fixed combination against other two-drug combinations used for high blood pressure. Evidence highlights what is known—and what is still uncertain—about the combination, and findings describe group patterns, not personal outcomes.

Common questions about НАРУНЕЛ (FAQ)

Q: What is the main medical use of НАРУНЕЛ as described in official documents?

A: Official product content provided under the name НАРУНЕЛ is associated with two different approved medical purposes. One is for the emergency treatment of known or suspected opioid overdose (Naloxone component). The other is for the daily management of essential hypertension (high blood pressure) using the Amlodipine/Valsartan combination.

Q: How long does it typically take before people start feeling the effects of НАРУНЕЛ?

A: The onset of effects depends on the product form. For the Naloxone nasal spray, the reversal of overdose symptoms typically begins within minutes. For the Amlodipine/Valsartan tablet used for high blood pressure, the full blood pressure-lowering effect is typically reached gradually, often over several days to two weeks.

Q: Do the effects of НАРУНЕЛ last all day, or does the dose wear off?

A: The duration of effect varies by the product's use. The Amlodipine/Valsartan tablet is formulated to provide sustained effects over a full day. However, the effects of the Naloxone nasal spray are temporary, typically lasting only 30 to 90 minutes, which is why immediate emergency monitoring is required.

Q: Can НАРУНЕЛ cause changes in mood or sleep patterns?

A: Official product information for the Amlodipine/Valsartan component lists some Central Nervous System (CNS) side effects. Uncommon reactions include somnolence (sleepiness) and vertigo. Regulatory documents note that patients have also uncommonly reported mood changes such as nervousness or feeling sad or empty.

Q: Is НАРУНЕЛ known to interact with common over-the-counter pain medications?

A: Official regulatory information indicates that the Valsartan component can interact with common pain relievers known as Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), such as ibuprofen. This interaction may potentially reduce the medication's blood pressure-lowering effect and is associated with an increased risk of changes in kidney function.

Q: Can I take vitamins or herbal supplements while using НАРУНЕЛ?

A: Regulatory information advises avoiding certain supplements while using the Amlodipine/Valsartan tablet. Specifically, the Valsartan component requires avoiding potassium supplements or potassium-containing salt substitutes. Furthermore, some multivitamins with minerals may decrease the effect of the Amlodipine component.

Q: What is the official information regarding the use of НАРУНЕЛ during pregnancy?

A: The official guidance on pregnancy varies significantly between the associated products. The Amlodipine/Valsartan tablet carries a regulatory warning and is generally not used during the second and third trimesters because of the potential for fetal injury or death. Conversely, the emergency use of Naloxone should not be withheld during a life-threatening situation.

Q: Can НАРУНЕЛ be used by people who have existing kidney conditions?

A: Regulatory documents note restrictions based on the component in question. The Amlodipine/Valsartan tablet is restricted or contraindicated for patients with severe renal (kidney) impairment. However, in a life-threatening emergency, the use of Naloxone is generally not prohibited, though close monitoring is required.

Q: Does НАРУНЕЛ cure the underlying condition it is prescribed for?

A: The Amlodipine/Valsartan tablet is approved for the management of high blood pressure, which is a chronic condition. Official product information confirms that the medication is used for management and control of symptoms, and it is not considered a cure for the underlying chronic disease.

Q: What is the active substance in the medicine НАРУНЕЛ?

A: The official content provided under the name НАРУНЕЛ lists two sets of active substances: Naloxone Hydrochloride (used in the nasal spray form) and the fixed-dose combination of Amlodipine and Valsartan (used in the oral tablet form).

Q: Where can I find the official prescribing information for НАРУНЕЛ?

A: Official prescribing information and regulatory labels are published by government drug databases. These resources include the FDA DailyMed, the EMA Summary of Product Characteristics (SmPC), and the NIH MedlinePlus Drug Information.

Q: What is the typical duration of treatment with НАРУНЕЛ?

A: The duration of treatment is based on the intended use. The Amlodipine/Valsartan tablet is intended for the long-term, chronic management of high blood pressure. The Naloxone component is designed for a single, immediate emergency use with conditional repeat dosing until medical assistance arrives.

Q: Does НАРУНЕЛ generally cause weight gain or weight loss?

A: For the Amlodipine/Valsartan tablet, some side effects related to fluid retention have been reported. Peripheral edema (swelling of hands/feet) and rapid weight gain are listed as common. Additionally, both weight increased and weight decreased have been listed as uncommon side effects for the Amlodipine component.

Q: Is it true that НАРУНЕЛ should be taken at a specific time of day?

A: The Amlodipine/Valsartan tablet for high blood pressure is generally taken once daily at the same time each day to help maintain consistent blood pressure control. This is as recommended in the official drug information.

Q: Does taking НАРУНЕЛ with food affect how well it is absorbed?

A: According to official product information for the Amlodipine/Valsartan tablet, the medication can be taken with or without food. This generally indicates that food does not significantly affect the absorption or effectiveness of the medication.

Q: What are the known contraindications listed in the official drug information for НАРУНЕЛ?

A: Regulatory documents list several conditions that generally preclude use. Contraindications for both products include a known hypersensitivity (severe allergic reaction) to the active substance or any of the inactive ingredients. The Amlodipine/Valsartan component is also contraindicated during the second and third trimesters of pregnancy.

Q: Is there a risk of becoming dependent on НАРУНЕЛ over time?

A: The Amlodipine/Valsartan tablet for high blood pressure is not associated with dependence or abuse risk. For the Naloxone component, its use may precipitate acute withdrawal symptoms in an individual who is opioid-dependent, which is a key safety consideration for monitoring.

Q: What happens if a dose of НАРУНЕЛ is missed? (General fact-check)

A: Official guidance for the Amlodipine/Valsartan tablet addresses missed doses by advising the patient to take the dose when remembered. However, if it is close to the time of the next scheduled dose, the missed dose is usually skipped, and the regular schedule is resumed.

Q: Is НАРУНЕЛ available as a generic version?

A: Official regulatory sources confirm that the fixed-dose combination of Amlodipine and Valsartan is available in generic form. This means that versions of the medication are accessible under different trade names.

Q: Why is a specific laboratory test sometimes required before starting НАРУНЕЛ?

A: Before and periodically during treatment with the Amlodipine/Valsartan tablet, tests are often required due to the Valsartan component. Official documents indicate that monitoring of serum potassium levels and renal function (kidney function) is necessary to ensure safety and detect early signs of side effects.

Q: Is it possible to split or crush the НАРУНЕЛ tablets?

A: Official drug information for the Amlodipine/Valsartan tablet generally directs that the medication should be swallowed whole and not to be broken, split, or crushed.

Q: Does НАРУНЕЛ have a known effect on blood pressure?

A: Yes, the medication has a known effect on blood pressure in both contexts. The Amlodipine/Valsartan tablet is specifically prescribed to lower high blood pressure. For the Naloxone component, the rapid reversal of opioid effects may cause adverse cardiovascular events, including a temporary increase in blood pressure.

Q: What is the official mechanism of action of НАРУНЕЛ?

A: Regulatory documents describe two distinct mechanisms. The Naloxone component acts as an Opioid Receptor Antagonist to block the effects of opioids. The Amlodipine/Valsartan tablet works through the combined action of a Calcium Channel Blocker (Amlodipine) and an Angiotensin II Receptor Blocker (Valsartan) to lower blood pressure.

Q: Is НАРУНЕЛ used for any conditions other than the main one listed? (Official labeling)

A: Official product labels list the two core indications associated with the name: Essential Hypertension and Opioid Overdose Reversal. Regulatory documents confirm that there are no other primary approved indications listed in the product's official labels for either component.

Q: What official resources provide patient information about НАРУНЕЛ?

A: Patient-facing information that is based on official labeling is provided by authoritative bodies. These resources include the FDA DailyMed Patient Information, the EMA Package Leaflet (PL), and the NIH MedlinePlus Drug Information.

Q: Is it necessary to stop taking НАРУНЕЛ gradually? (Safety clarification)

A: Official guidance for the Amlodipine/Valsartan tablet indicates that the medication should not be stopped abruptly. This is because sudden discontinuation may lead to a sudden increase in blood pressure or worsening of angina (chest pain).

Q: Why is a specific warning given about operating heavy machinery while using НАРУНЕЛ?

A: Official warnings are included because certain common side effects associated with the Amlodipine/Valsartan tablet can impair alertness. These effects, such as dizziness or somnolence (sleepiness), may affect the ability to drive or safely operate heavy machinery.

Official Storage and Disposal Requirements

Storage of НАРУНЕЛ (Naloxone Hydrochloride Nasal Spray) must strictly follow the requirements documented in official regulatory labeling to ensure product stability and readiness for emergency use.

The official labeling mandates these specific storage conditions and handling rules, including keeping the sealed device protected from freezing and light. Proper disposal following pharmaceutical waste guidelines is required for all used or unused products.